Huntingtons Disease Therapeutics Market by Type, End-User

List of Tables

The Huntington`s Disease Therapeutics Market is projected to reach USD 1,561.74 million by 2030 from USD 448.35 million in 2022, at a CAGR of 16.88% during the forecast period.

Global Huntington`s Disease Therapeutics Market

KEY MARKET STATISTICS
Base Year Value [2022]	USD 448.35 million
Estimated Year Value [2023]	USD 516.01 million
Forecast Year Value [2030]	USD 1,561.74 million
CAGR (%)	16.88%

Huntington`s Disease Therapeutics Market - IMG1

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Huntington`s Disease Therapeutics Market.

Based on Type, market is studied across Disease-modifying Therapies, Gene Therapies, Medication, Occupational Therapies, and Symptomatic Treatment. The Symptomatic Treatment is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Hospitals, Long-Term Care Facilities, and Specialty Clinics. The Long-Term Care Facilities is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Huntington`s Disease Therapeutics Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Huntington`s Disease Therapeutics Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Huntington`s Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Alterity Therapeutics Limited, Annexon Biosciences, AOP Orphan Pharmaceuticals GmbH, Bausch Health Companies Inc., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Ionis Pharmaceuticals Inc., Ipsen S.A., Lupin Limited, Medesis Pharma SA, Mitochon Pharmaceuticals, Inc., NeuExcell Therapeutics Inc, Neurocrine Biosciences, Inc., Novartis AG, Pfizer Inc., Prilenia Therapeutics B.V., PTC Therapeutics Inc., SOM Innovation Biotech S.A., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., uniQure N.V., Vaccinex Inc., and Vertex Pharmaceuticals Incorporated.

The report offers valuable insights on the following aspects:

1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.

2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.

3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.

4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.

5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast for the Huntington`s Disease Therapeutics Market?

2. Which products, segments, applications, and areas hold the highest investment potential in the Huntington`s Disease Therapeutics Market?

3. What is the competitive strategic window for identifying opportunities in the Huntington`s Disease Therapeutics Market?

4. What are the latest technology trends and regulatory frameworks in the Huntington`s Disease Therapeutics Market?

5. What is the market share of the leading vendors in the Huntington`s Disease Therapeutics Market?

6. Which modes and strategic moves are suitable for entering the Huntington`s Disease Therapeutics Market?

Product Code: MRR-69324464D2C9

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Huntington`s Disease Therapeutics Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increase in need for drugs to control Huntington's disease symptoms
  - 5.1.1.2. Rising government initiatives to increase awareness about Huntington's disease
- 5.1.2. Restraints
  - 5.1.2.1. High cost associated with advanced treatments
- 5.1.3. Opportunities
  - 5.1.3.1. Increase in clinical research activities for drug development for Huntington's disease
  - 5.1.3.2. Growing drug approvals for the treatment of Huntington's disease patients
- 5.1.4. Challenges
  - 5.1.4.1. Problems associated with strict regulatory policies for development of Huntington's disease drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Huntington`s Disease Therapeutics Market, by Type

6.1. Introduction
6.2. Disease-modifying Therapies
6.3. Gene Therapies
6.4. Medication
6.5. Occupational Therapies
6.6. Symptomatic Treatment

7. Huntington`s Disease Therapeutics Market, by End-User

7.1. Introduction
7.2. Hospitals
7.3. Long-Term Care Facilities
7.4. Specialty Clinics

8. Americas Huntington`s Disease Therapeutics Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Huntington`s Disease Therapeutics Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Huntington`s Disease Therapeutics Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

12.1. Key Company Profiles
- 12.1.1. Alnylam Pharmaceuticals, Inc.
- 12.1.2. Alterity Therapeutics Limited
- 12.1.3. Annexon Biosciences
- 12.1.4. AOP Orphan Pharmaceuticals GmbH
- 12.1.5. Bausch Health Companies Inc.
- 12.1.6. Dr. Reddy's Laboratories Ltd.
- 12.1.7. Hikma Pharmaceuticals PLC
- 12.1.8. Ionis Pharmaceuticals Inc.
- 12.1.9. Ipsen S.A.
- 12.1.10. Lupin Limited
- 12.1.11. Medesis Pharma SA
- 12.1.12. Mitochon Pharmaceuticals, Inc.
- 12.1.13. NeuExcell Therapeutics Inc
- 12.1.14. Neurocrine Biosciences, Inc.
- 12.1.15. Novartis AG
- 12.1.16. Pfizer Inc.
- 12.1.17. Prilenia Therapeutics B.V.
- 12.1.18. PTC Therapeutics Inc.
- 12.1.19. SOM Innovation Biotech S.A.
- 12.1.20. Sun Pharmaceutical Industries Limited
- 12.1.21. Teva Pharmaceutical Industries Ltd.
- 12.1.22. uniQure N.V.
- 12.1.23. Vaccinex Inc.
- 12.1.24. Vertex Pharmaceuticals Incorporated
12.2. Key Product Portfolio

13. Appendix

13.1. Discussion Guide
13.2. License & Pricing